Bottom line
RYCFX vs PBE: the short answer
RYCFX (Biotechnology Fund) and PBE (Invesco Biotechnology & Genome ETF) are both mutual funds.
But RYCFX is far broader, holding 74 positions to 33 for PBE, so beyond the top names it adds exposure PBE doesn't have.
PBE is cheaper at 0.59% vs 2.38% — a difference of $179 a year per $10,000 invested.
Over five years, PBE returned +3.4% a year vs +3.0% for RYCFX.
Updated Nov 19, 2026
RYCFX vs PBE side by side
| RYCFX | PBE | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | Guggenheim | Invesco |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 0.59% |
| Annual cost per $10k | $238 | $59 |
| 10-yr cost on $10k (prospectus) | $2,763 | $738 |
| Max front load | 0% | None |
| 12b-1 fee | 1% | — |
| 1-yr return | +28.4% | +24.7% |
| 5-yr return (annualized) | +3.0% | +3.4% |
| 10-yr return (annualized) | +4.8% | +5.2% |
| Best quarter | +28.0% | +25.3% |
| Worst quarter | −22.7% | −24.3% |
| Net assets (fund) | $136.8M | $281.9M |
| Number of holdings | 74 | 33 |
| Portfolio turnover | 75% | 103% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | PBE | Difference |
|---|---|---|---|
| 2025 | +29.4% | +24.7% | +4.7% |
| 2024 | −1.7% | +1.1% | −2.8% |
| 2023 | +5.0% | +3.7% | +1.3% |
| 2022 | −13.9% | −10.8% | −3.2% |
| 2021 | +0.8% | +1.6% | −0.8% |
| 2020 | +20.9% | +25.5% | −4.6% |
| 2019 | +23.8% | +18.3% | +5.5% |
| 2018 | −9.9% | +0.2% | −10.1% |
| 2017 | +28.4% | +22.4% | +6.0% |
| 2016 | −20.3% | −23.0% | +2.7% |
Source: Fund prospectus bar charts
Holdings overlap
10 of RYCFX's top 25 holdings also appear in PBE's top 25.
| Holding | RYCFX | PBE |
|---|---|---|
| Amgen Inc | 5.05% | 5.22% |
| Gilead Sciences Inc | 4.49% | 4.43% |
| Vertex Pharmaceuticals Inc | 4.32% | 4.99% |
| Regeneron Pharmaceuticals Inc | 2.93% | 5.47% |
| Alnylam Pharmaceuticals Inc | 2.36% | 3.17% |
| Biogen Inc | 2.13% | 4.79% |
| Illumina Inc | 1.94% | 3.51% |
| United Therapeutics Corp | 1.72% | 4.08% |
| Incyte Corp | 1.62% | 3.06% |
| Neurocrine Biosciences Inc | 1.52% | 2.66% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
PBE top 10
- Invesco Private Prime Fund — 12.89%
- Regeneron Pharmaceuticals, Inc. — 5.47%
- Amgen Inc. — 5.22%
- CareDx, Inc. — 5.04%
- Vertex Pharmaceuticals Inc. — 4.99%
- Invesco Private Government Fund — 4.97%
- Royalty Pharma PLC — 4.94%
- Biogen Inc. — 4.79%
- Gilead Sciences, Inc. — 4.43%
- United Therapeutics Corp. — 4.08%
FAQ
What is the difference between RYCFX and PBE?
Which is cheaper, RYCFX or PBE?
Should I own both RYCFX and PBE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.